Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate CIS43LS in Healthy Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 17.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Able and willing to complete the informed consent process~ 2. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process~ 3. Available for clinical follow-up through the last study visit~ 4. 18 to 50 years of age~ 5. In good general health without clinically significant medical history~ 6. Physical examination without clinically significant findings within the 56 days prior to enrollment~ 7. Weight \<= 115 kg (for all groups except Groups 5, 10, and 16) and \< 100 kg for Group 15~ 8. Adequate venous access if assigned to an IV group or adequate subcutaneous tissue if assigned to an SC group~ 9. Willing to have blood samples collected, stored indefinitely, and used for research purposes~ 10. Agrees to participate in a controlled human malaria infection (CHMI) and to comply with post-CHMI follow-up requirements (except Group 4B)~ 11. Agrees to refrain from blood donation to blood banks for 3 years following participation in CHMI (except Group 4B)~ 12. Agrees not to travel to a malaria endemic region during the entire course of study participation~      Laboratory Criteria within 56 days prior to enrollment:~ 13. White Blood Cell (WBC) 2,500-12,000/mm\^3~ 14. WBC differential either within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval~ 15. Platelets = 125,000 - 500,000/mm\^3~ 16. Hemoglobin within institutional normal range or accompanied by the PI or designee approval~ 17. Creatinine \<= 1.1 x upper limit of normal (ULN)~ 18. Alanine aminotransferase (ALT) \<= 1.25 x ULN~ 19. Negative for HIV infection by an FDA approved method of detection~      Laboratory Criteria documented any time prior to enrollment:~ 20. Negative sickle cell screening test~ 21. Negative troponin test (except Group 4B)~ 22. Electrocardiogram (ECG) without clinically significant abnormalities (examples may include: pathologic Q waves, significant ST-T wave changes, left ventricular hypertrophy, any non-sinus rhythm excluding isolated premature atrial contractions, right or left bundle branch block, advanced A-V heart block). ECG abnormalities determined by a cardiologist to be clinically insignificant as related to study participation do not preclude study enrollment (except Group 4B)~ 23. No evidence of increased cardiovascular disease risk; defined as \>10% five-year risk by the non-laboratory method (except Group 4B)~      Criteria Specific to Women:~ 24. Postmenopausal for at least 1 year, post-hysterectomy or bilateral oophorectomy, or if of childbearing potential:~      1. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on day of enrollment, and prior to product administration and CHMI, and~     2. Agrees to use an effective means of birth control through the duration of study participation~* EXCLUSION CRITERIA:~  1. Woman who is breast-feeding or planning to become pregnant during study participation~ 2. Previous receipt of a malaria vaccine~ 3. History of malaria infection~ 4. History of severe infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) defined per FDA guidance~ 5. Active SARS-CoV-2 infection~ 6. Any history of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the study~ 7. Hypertension that is not well controlled~ 8. Receipt of any investigational study product within 28 days prior to enrollment (note: Emergency Use Authorization Coronavirus Disease 2019 (COVID-19) vaccine is not exclusionary)~ 9. Receipt of any live attenuated vaccines within 28 days prior to enrollment~ 10. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with intramuscular injections or blood draws~ 11. History of a splenectomy, sickle cell disease or sickle cell trait~ 12. History of skeeter syndrome or anaphylactic response to mosquito-bites (except Group 4B)~ 13. Known intolerance to chloroquine phosphate, atovaquone or proguanil (except Group 4B)~ 14. Use or planned use of any drug, including antibiotics, with antimalarial activity within 4 weeks prior to CHMI~ 15. History of psoriasis or porphyria, which may be exacerbated after treatment with chloroquine (except Group 4B)~ 16. Anticipated use of medications known to cause drug reactions with chloroquine or atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and kaolin (except Group 4B)~ 17. Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer, including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, autoimmune disease, psychiatric disorders, heart disease, or cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Part A, Group 1: CIS43LS (5 mg/kg IV) (Type: EXPERIMENTAL): CIS43LS (5 mg/kg) administered by intravenous (IV) infusion (Day 0)
- Part A, Group 2: CIS43LS (5 mg/kg SC) (Type: EXPERIMENTAL): CIS43LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
- Part A, Group 3: CIS43LS (20 mg/kg IV) (Type: EXPERIMENTAL): CIS43LS (20 mg/kg) administered by IV infusion (Day 0)
- Part A, Group 4A: CIS43LS (40 mg/kg IV) (Type: EXPERIMENTAL): CIS43LS (40 mg/kg) administered by IV infusion (Day 0)
- Part A, Group 4B: CIS43LS (40 mg/kg IV) (Type: EXPERIMENTAL): CIS43LS (40 mg/kg) administered by IV infusion (Day 0)
- Part A, Group 5: CHMI Controls (Type: NO_INTERVENTION): Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI); however, Group 5 did not undergo CHMI because of restrictions related to coronavirus disease 2019 (COVID-19)
- Part B, Group 6: CIS43LS (5 mg/kg SC) (Type: EXPERIMENTAL): CIS43LS (5 mg/kg) administered by SC injection (Day 0)
- Part B, Group 7: CIS43LS (20 mg/kg IV) (Type: EXPERIMENTAL): CIS43LS (20 mg/kg) administered by IV infusion (Day 0)~Part B, Group 7 participants included participants previously enrolled in Part A who received either 5 mg/kg IV (1), 5 mg/kg SC (1) or 20 mg/kg IV (2) in the first part of the study and newly enrolled Part B participants
- Part B, Group 8: CHMI [CIS43LS (40 mg/kg IV) in Part A] (Type: OTHER): Part B, Group 8 participants included participants previously enrolled in Part A who received CIS43LS (40 mg/kg IV) in the first part of the study but did not receive CIS43LS in Part B of the study. Group 8 participants were enrolled to complete the controlled human malaria infection (CHMI).
- Part B, Group 9: CIS43LS (40 mg/kg IV) (Type: EXPERIMENTAL): CIS43LS (40 mg/kg) administered by IV infusion (Day 0)
- Part B, Group 10: CHMI Controls (Type: OTHER): Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI)
- Part C, Group 11: CIS43LS (1 mg/kg IV) (Type: EXPERIMENTAL): CIS43LS (1 mg/kg) administered by IV infusion (Day 0)
- Part C, Group 12: CIS43LS (5 mg/kg IV) (Type: EXPERIMENTAL): CIS43LS (5 mg/kg) administered by IV infusion (Day 0)
- Part C, Group 13: CIS43LS (5 mg/kg SC) (Type: EXPERIMENTAL): CIS43LS (5 mg/kg) administered by SC injection (Day 0)
- Part C, Group 14: CIS43LS (10 mg/kg IV) (Type: EXPERIMENTAL): CIS43LS (10 mg/kg) administered by IV infusion (Day 0)
- Part C, Group 15: CIS43LS (10 mg/kg SC) (Type: EXPERIMENTAL): CIS43LS (10 mg/kg) administered by SC injection (Day 0)
- Part C, Group 16: CHMI Controls (Type: OTHER): Control participants who did not receive CIS43LS and were enrolled to complete the controlled human malaria infection (CHMI)

Based on this trial design, predict the completion outcome and termination type (if applicable).